Influvac Sub-Unit (Influenza Virus B/Austria/1359417/2021-Like Strain (B/Austria/1359417/2021, Bvr-26), Influenza A/Vic)

The vaccine contains purified hemagglutinin proteins from selected influenza A and B strains. After injection, these proteins are recognized by the immune system, prompting B‑cells and T‑cells to generate specific antibodies. The resulting antibodies neutralise the virus if the person is later exposed, providing protective immunity.

The dosage and schedule of Influvac Sub-Unit are determined by the prescribing healthcare professional based on age, health status, and local immunisation guidelines. Typically, a single dose is given annually, but the exact volume and route are specified by the prescriber.

Safety data for use during pregnancy or lactation are limited. Healthcare providers should evaluate the potential benefits and risks before vaccinating pregnant or breastfeeding individuals. In many regions, inactivated influenza vaccines are considered acceptable when the benefits of preventing flu outweigh theoretical risks.

To place an order, submit an enquiry on the product page at gnhindia.com, indicating the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics if needed), and necessary import documentation.

Influvac Sub-Unit is a subunit vaccine that contains only purified viral surface proteins, offering a well‑tolerated safety profile compared with whole‑virus or live‑attenuated vaccines. It targets the same influenza strains as other seasonal vaccines but may have fewer reactogenic components, making it suitable for individuals with specific sensitivities.

The vaccine must be stored refrigerated between 2 °C and 8 °C. It should be kept in the original packaging to protect from light, must not be frozen, and should not be shaken. Proper cold‑chain management is essential to maintain potency until administration.

Influvac Sub-Unit is administered by a qualified healthcare professional via intramuscular or subcutaneous injection, typically into the deltoid muscle of the upper arm. The injection site is cleaned with an antiseptic, and the dose is delivered using a sterile needle and syringe.

Serious adverse events, although rare, include anaphylactic reactions, Guillain‑Barré syndrome, high fever, seizures, and myocarditis. Patients should be observed for a short period after vaccination and instructed to seek immediate medical care if they experience symptoms such as difficulty breathing, swelling of the face or throat, or severe neurological signs.

Individuals with a known severe allergy to any component of the vaccine, including egg protein, should avoid it. Infants younger than 6 months are not eligible. Persons with a history of severe allergic reaction to a previous influenza vaccine dose should consult their clinician before receiving Influvac Sub-Unit.